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and HTN/DYS treatment rose from 0.6% to 1.3% (+24% pa). In 2001, 29.9% of those
aged >40 years had a history of HTN and 24.6% of this group had been treated for HTN.
Furthermore, 17.7% had a history of DYS of which 7.4% had been treated for this condi-
tion. Moreover, 9.7% had a history of concurrent HTN/DYS of which 5.0% had been
treated for both conditions.
Conclusion: Incident diagnosis and treatment of DYS and HTN/DYS more than doubled
between 1997 and 2001. Treatment of HTN increased, despite a reduction in incident
detection. There was a marked trend towards more aggressive treatment of DYS. Never-
theless, the vast majority of patients with HTN and DYS were not being treated for these
conditions. Therefore, there is a considerable opportunity to better manage cardiovascu-
lar risk by improving the treatment of HTN and DYS.
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858-1 Risk Factors for and Inadequate Prophylaxis Against 
Upper Extremity Deep Vein Thrombosis
Hylton V. Joffe, Nils Kucher, Victor F. Tapson, Samuel Z. Goldhaber, The DVT FREE 
Steering Committee, Brigham and Women's Hospital, Harvard Medical School, Boston, 
MA, Duke University Medical Center, Durham, NC
Background: Upper extremity deep vein thrombosis (UEDVT) is becoming more com-
mon with widespread use of pacemakers, implantable cardioverter-defibrillators, and
long-term central venous catheters.
Methods: To improve our knowledge of UEDVT, we describe 592 patients with UEDVT
(292 women, 300 men) from DVT FREE, a prospective, United States multicenter regis-
try of 5,451 patients with ultrasound-confirmed deep vein thrombosis (DVT) enrolled at
183 sites over 6 months.
Results: The UEDVT patients were younger (mean age 57.8 ± 17.8 vs. 64.2 ± 16.8
years; p<.001) than the lower extremity DVT patients. Surgery within 3 months of the
DVT diagnosis (55% vs. 36%), central venous catheters (55% vs. 10%), and cancer
(39% vs. 32%) were more frequent in the UEDVT than lower extremity DVT patients
(p<.001). The best independent predictors of UEDVT were indwelling central venous
catheters, age < 65 years, and Body Mass Index < 25 kg/m2 (Figure). Of the 592 UEDVT
patients, 402 (68%) were diagnosed as inpatients. The median time from hospitalization
to UEDVT diagnosis was 7 days (interquartile range 2-14 days). The most common pro-
phylaxis regimens were subcutaneous unfractionated heparin, warfarin, and low molecu-
lar weight heparin, used in 10%, 10%, and 6% of UEDVT patients, respectively. However,
only 65 (16%) UEDVT inpatients were receiving prophylaxis at the time of diagnosis.
Conclusion: Most hospitalized patients at risk for UEDVT do not receive effective pro-
phylaxis even though there is opportunity to intervene.
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858-2 Prevention of Flight-Related Thrombosis With Elastic 
Stockings: The JPA-Study, Final Analysis
Belcaro Giovanni, Maria Rosaria Cesarone, Andrew N. Nicolaides, George Geroulakos, 
Mark Dugall, Andrea Di Renzo, Sandeep Shah, Art Pulitzer, Lonflit Consortium, London, 
United Kingdom, San Valentino Vascular Screening Project and Chieti University, 
Pescara, Italy
The aim of this study was to evaluate deep venous thrombosis (DVT) prophylaxis with
specific elastic stockings in long-haul flights (11-13 hours), in high risk subjects. A group
of 446 subjects was included; 58 were excluded for several problems including concomi-
tant treatments; 388 were randomised (stockings vs controls) to evaluate prophylaxis
with below-knee stockings. An exercise program was used in both groups. Scholl (UK)
Flight Socks (14-17 mmHg of pressure at the ankle) were used. DVT was diagnosed with
high resolution ultrasound scanning. The femoral, popliteal and tibial veins were scanned
before and within 90 minutes after the flights. Out of the included subjects 180 controls
and 178 treated subjects completed the study. Drop-outs (30) were due to flight connec-
tion problems. Age, sex, risk distributions were comparable in the two groups. In the
treatment group (mean age 44.5; SD 12; males 55%) two limited, distal, below-knee
DVTs were observed (1.1%). In the control group (mean age 45; SD 11; males 66%) 7
subjects (3.8%) had a DVT and 5 a superficial thombosis (2.7%) for a total of 6.5% of
thrombotic events. The difference in DVT incidence is significant (P<0.005; 6 times
greater in the control group). Intention to treat analysis counts 29 failures in the control
group (17 lost to follow-up + 12 thromboses) out of 197 subjects (14.7%) versus 15 fail-
ures (2 DVTs)(7.8%) in the treatment group (P<0.05). The tolerability of the stockings
was very good; there were no side effects. Events were asymptomatic in 97% of sub-
jects. In conclusion Scholl Flight Socks are effective in reducing the incidence of DVT in
high-risk subjects.
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858-3 Subcutaneous Treprostinil Therapy Evokes Both 
Survival Benefit and Continuous Dose-Dependent 
Efficacy Improvements in Patients With Pulmonary 
Arterial Hypertension: A Long-Term European 
Multicentre Analysis of 112 Patients
Irene Lang, Miguel Gomez-Sanchez, Meinhard Kneussl, Pilar Escribano, Robert Naeije, 
Jean-Luc Vachiery, Hopital Erasme, Bruxelles, Belgium, Vienna General Hospital, 
Vienna, Austria
BACKGROUND: Subcutaneous infusion of the prostacyclin analogue, treprostinil
(Remodulin®), is an effective treatment for pulmonary arterial hypertension (PAH).Unlike
epoprostenol therapy, treprostinil does not require the insertion of a permanent central
venous catheter, thus reducing the risk of serious complications. The aim of this multi-
centre analysis was to investigate whether treprostinil evoked survival benefits and con-
tinuous dose-dependent efficacy improvements in patients with PAH.
METHODS: 112 patients (83 female, 29 male) with PAH (New York Heart Association
Class I-IV; mean age 47.4±12.5 years) received long-term treprostinil therapy (up to 75
ng/kg/min). During the assessment period, exercise capacity was measured at three-
monthly intervals via a six-minute walk test (6MW) and Borg Dyspnea scoring. Changes
to NYHA classification status were also monitored.
RESULTS: Survival benefits are shown in Figure One. Mean 6MW scores increased sig-
nificantly from 323±97 m at baseline to 433± 85m after 24 months. Significant improve-
ments in Borg Dyspnea scores were also observed from a mean baseline value of
5.3±2.6 to 4.0±2.8. NYHA functional class significantly improved from 3.1±0.5 to 2.3±0.7.
CONCLUSIONS: Long-term subcutaneous treprostinil therapy evokes continuous
improvements in exercise tolerance and symptoms in patients with PAH. These improve-
ments occur in a dose-dependent manner. Our results also suggest that treprostinil ther-
apy confers survival benefit. 
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858-4 C-Reactive Protein Levels and Race/Ethnicity
Michelle A. Albert, Robert J. Glynn, Julie Buring, Paul M. Ridker, Brigham and Women's 
Hospital, Boston, MA, Harvard Medical School, Boston, MA
Background:
In the United States, cardiovascular morbidity and mortality rates are higher among Black
women than among White women, while rates are lower among Asian women. C-reac-
tive Protein (CRP), a marker of inflammation, is an independent predictor of cardiovascu-
lar risk. However, data on CRP among various race/ethnic groups are sparse.
Methods and Results:
The distribution of CRP levels was compared among 24,455 White, 475 Black, 357 Asian
and 254 Hispanic women, all of whom are participants in the Women’s Health Study
(WHS). Median CRP levels were significantly higher among Black women (2.96 mg/L,
interquartile range (IQR) = 1.19, 5.86) than their White (2.02 mg/L, IQR = 0.81, 4.37),
Hispanic (2.06 mg/L, IQR = 0.88, 4.88), and Asian (1.12 mg/L, IQR = 0.48, 2.25) counter-
parts. As expected, women taking hormone replacement therapy (HRT) had higher base-
line CRP levels than women not taking HRT. No differences in LDL cholesterol or total
cholesterol levels were observed between ethnic groups. In multivariate regression mod-
els, body mass index (BMI) was a significant
(p < 0.001) predictor of elevated CRP concentrations among all race/ethnic groups, and
control for BMI substantially attenuated the differences noted in CRP levels across race/
ethnic groups, particularly among Black women. However, control for all measured modi-
fiable risk factors for cardiovascular disease did not entirely explain the CRP differences.
Conclusion: Among these women, the distribution of CRP levels varied among different
race/ethnic groups in a manner which parallels observed population based differences in
cardiovascular morbidity and mortality rates. Modifiable risk factors did not entirely
account for the observed race/ethnic differences noted in CRP levels.
